Bioxcel Therapeutics (BTAI) Fundamental Analysis: Revenue, Earnings & Valuation

1.69 / 10

Underperform

Fundamental analysis rates BTAI as Underperform, scoring roughly 1.7/10. Revenue YoY plummets ~‑80%, and long‑term debt to working capital is elevated, weighing on outlook. Conversely, inventory turnover (0.232) and cost‑of‑sales ratio (34.2%) show efficiency, yet overall fundamentals remain weak.

Analysis Checks(4/10)

Revenue-MV

Value-3.67

Score1/3

Weight23.97%

1M Return4.09%

Total operating revenue (YoY growth rate %)

Value-79.68

Score1/3

Weight-1.89%

1M Return-0.38%

Inventory turnover ratio

Value0.23

Score3/3

Weight-4.74%

1M Return-0.93%

Current liabilities / Total liabilities (%)

Value28.27

Score3/3

Weight8.97%

1M Return1.67%

PB-ROE

Value-0.75

Score1/3

Weight39.01%

1M Return7.56%

Long-term debt to working capital ratio (%)

Value14.53

Score1/3

Weight-3.24%

1M Return-0.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-5.59%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value-79.68

Score1/3

Weight-1.49%

1M Return-0.30%

Cost of sales ratio (%)

Value34.20

Score3/3

Weight1.40%

1M Return0.26%

Asset-MV

Value-0.49

Score1/3

Weight43.61%

1M Return6.31%

Is BTAI undervalued or overvalued?

BTAI scores 1.69/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -10887.38% net margin, -0.44 P/E ratio, -0.35 P/B ratio, and 75.63% earnings growth, these metrics solidify its Underperform investment rating.